SGLT-2抑制剂在儿童慢性肾脏病中的应用:进展、挑战与机遇
本文是一篇针对2023年多利益相关方研讨会的社论,讨论SGLT-2抑制剂在儿童慢性肾脏病中的研发。成人试验显示强效肾脏和心血管获益,但儿童因监管豁免缺乏研究。研讨会强调紧迫医疗需求,同时指出儿童CKD以先天性异常和非肾小球疾病为主、进展较慢、蛋白尿较少,限制成人数据外推,且需关注脱水、感染及生长骨骼神经发育等安全性问题。近期监管行动和即将开展的儿童试验标志进展。
要点
- 儿童CKD病因与成人不同,以先天性异常和非肾小球疾病为主,进展较慢且蛋白尿较少。
- 儿童特异性安全性关注包括脱水、感染及生长、骨骼和神经发育影响。
- 需儿科特异性终点和生物标志物,包括心血管结局,并开展国际合作试验。
核心结论
- SGLT-2抑制剂在儿童CKD中缺乏研究,但存在紧迫医疗需求,近期监管行动和即将开展的试验标志进展。
研究设计与样本
- 本文为社论,评论2023年多利益相关方研讨会关于儿童CKD中SGLT-2抑制剂研发的报告。
主要发现
- 成人试验显示强效肾脏和心血管获益,但儿童研究因监管豁免被排除。
- 儿童CKD以先天性异常和非肾小球疾病为主,进展较慢且蛋白尿较少,限制成人数据外推。
- 儿童特异性安全性关注包括脱水、感染及生长、骨骼和神经发育影响。
- 需儿科特异性终点和生物标志物,包括心血管结局。
- 近期监管行动包括美国FDA要求儿童恩格列净研究,即将开展EMPA-KIDNEY-Kids和DOUBLE-PROTECT Alport试验。
临床怎么用
- 临床应关注儿童CKD中SGLT-2抑制剂的安全性和有效性证据缺口,并参与国际合作试验。
局限性
- 儿童研究缺乏,成人数据外推受限,安全性问题需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This editorial comments on the report on a 2023 multistakeholder workshop addressing the development of sodium-glucose cotransporter-2 inhibitors for children with chronic kidney disease. Despite adult trials showing strong renal and cardiovascular benefits, pediatric studies are lacking because regulatory waivers excluded this population. Workshop participants emphasized urgent medical need, but also highlighted challenges: pediatric chronic kidney disease differs from adults, with congenital anomalies and nonglomerular disorders predominating, slower progression, and less proteinuria, limiting extrapolation from adult data. Safety concerns specific to children include dehydration, infections, and growth, bone, and neurodevelopmental effects. Lessons from adult trials underscore the need for pediatric-specific end points and biomarkers, including for cardiovascular outcomes. Recent regulatory actions, including the US Food and Drug Administration's mandate for pediatric empagliflozin studies, mark progress. Upcoming clinical trials (A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease [EMPA-KIDNEY-Kids], Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients [DOUBLE-PROTECT] Alport) will require collaborative international efforts by the pediatric nephrology community to close the knowledge gap and ensure equitable access to renoprotective therapies for children with chronic kidney disease.
引用
- Schaefer F. SGLT-2 inhibition in pediatric CKD: advances, challenges, and opportunities. Kidney Int. 2026. PMID: 41485792. doi:10.1016/j.kint.2025.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。